Lantheus Holdings received FDA approval for TAUKLARIFY (florquinitau F 18 injection), a new radiodiagnostic agent.
The agent identifies tau neurofibrillary tangle pathology in the brains of adults with cognitive impairment.
Clinicians will use the PET imaging tool to evaluate patients for Alzheimer's disease.
TAUKLARIFY complements existing amyloid PET scans to provide a more complete diagnostic profile.
Lantheus will support Alzheimer's therapeutic programs through its Pharma Solutions business.
The company is currently evaluating the path for broader commercial availability.